Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,786JPY
13 Sep 2019
Change (% chg)

¥67 (+1.80%)
Prev Close
¥3,719
Open
¥3,734
Day's High
¥3,831
Day's Low
¥3,722
Volume
8,576,900
Avg. Vol
5,317,558
52-wk High
¥4,943
52-wk Low
¥3,401

Latest Key Developments (Source: Significant Developments)

Takeda Issues U.S. Recall Of NATPARA For Injection Due To The Potential For Rubber Particulate
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ISSUES US RECALL OF NATPARA® (PARATHYROID HORMONE) FOR INJECTION DUE TO THE POTENTIAL FOR RUBBER PARTICULATE.TAKEDA - RECALL IS EFFECTIVE IMMEDIATELY DUE TO POTENTIAL ISSUE RELATED TO RUBBER PARTICULATES ORIGINATING FROM RUBBER SEPTUM OF NATPARA CARTRIDGE.TAKEDA PHARMACEUTICAL CO LTD - RECALL IS BEING CONDUCTED AFTER DISCUSSIONS WITH FDA.  Full Article

Kamada Says Will Now Continue To Produce Glassia For Takeda Through 2021
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Kamada Ltd ::KAMADA ANNOUNCES EXTENSION OF GLASSIA® [ALPHA1-PROTEINASE INHIBITOR (HUMAN)] SUPPLY AND DISTRIBUTION AGREEMENT WITH TAKEDA THROUGH 2021 AND EXPECTED TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA.KAMADA LTD - KAMADA WILL NOW CONTINUE TO PRODUCE GLASSIA FOR TAKEDA THROUGH 2021.KAMADA LTD - PROJECTS TOTAL REVENUES FROM SALES OF GLASSIA TO TAKEDA DURING YEARS 2019-2021 WILL BE IN RANGE OF $155 MILLION TO $180 MILLION.KAMADA LTD - REITERATING ITS FULL-YEAR 2019 REVENUE GUIDANCE OF $125 MILLION TO $130 MILLION.KAMADA LTD - PLANS TO PROVIDE ITS 2020 REVENUE GUIDANCE BY END OF 2019.  Full Article

Sosei Heptares And Takeda Enter Into New Partnership
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES AND TAKEDA ENTER INTO NEW STRATEGIC MULTI-TARGET RESEARCH, DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP.CO IS ELIGIBLE TO RECEIVE UP TO $26 MILLION IN UPFRONT, NEAR-TERM PAYMENTS, IN ADDITION TO RESEARCH FUNDING OVER AGREEMENT TERM.  Full Article

Health Canada Has Authorized Vyvanse For The Treatment Of Attention Deficit/Hyperactivity Disorder (Adhd)1
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::HEALTH CANADA HAS AUTHORIZED VYVANSE® (LISDEXAMFETAMINE DIMESYLATE), THE FIRST AND ONLY, CHEWABLE TABLET FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)1*.TAKEDA CANADA - HEALTH CANADA HAS AUTHORIZED A CHEWABLE TABLET OF VYVANSE.TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE INDICATED FOR TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER IN ADULTS AGED 18 AND OLDER.TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE EXPECTED TO BE AVAILABLE IN FALL 2019..  Full Article

Takeda Pharmaceutical Says Its Hybrid Bonds With Aggregate Principal Amount Of 500 Billion Yen Were Priced Friday
Friday, 31 May 2019 

May 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SAYS ITS HYBRID BONDS WITH AGGREGATE PRINCIPAL AMOUNT OF 500 BILLION YEN WERE PRICED FRIDAY.INTEREST RATE IS 1.72% PER ANNUM.MATURITY DATE IS JUNE 6, 2079.  Full Article

U.S. FDA Approves Gattex (Teduglutide) For Children With Short Bowel Syndrome
Friday, 17 May 2019 

May 17 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::U.S. FDA APPROVES GATTEX® (TEDUGLUTIDE) FOR CHILDREN 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS).TAKEDA PHARMACEUTICAL CO LTD - FDA APPROVED EXTENDING INDICATION OF GATTEX.  Full Article

Paulson & Co. Ups In Red Hat; Dissolves In Nielsen Holdings
Wednesday, 15 May 2019 

May 15 (Reuters) - Paulson & Co::PAULSON & CO. INC UPS SHARE STAKE IN RED HAT INC BY 11.5 PERCENT TO 420,500 SHARES - SEC FILING.PAULSON & CO. INC DISSOLVES SHARE STAKE IN NIELSEN HOLDINGS PLC - SEC FILING.PAULSON & CO. INC TAKES SHARE STAKE OF 13.2 MILLION SPONSORED ADS IN TAKEDA PHARMACEUTICAL CO LTD - SEC FILING.PAULSON & CO. INC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Takeda And Frazier Healthcare Partners Announce Collaboration To Launch Phathom Pharmaceuticals
Wednesday, 15 May 2019 

May 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND FRAZIER HEALTHCARE PARTNERS ANNOUNCE COLLABORATION TO LAUNCH PHATHOM PHARMACEUTICALS.TAKEDA PHARMACEUTICAL CO LTD - COLLABORATION TO LAUNCH PHATHOM PHARMACEUTICALS.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA HAS GRANTED A LICENSE TO PHATHOM FOR DEVELOPMENT AND EXCLUSIVE COMMERCIALIZATION RIGHTS TO VONOPRAZAN.TAKEDA PHARMACEUTICAL CO LTD - PHATHOM HAS COMPLETED A $90 MILLION CROSSOVER FINANCING AND $50 MILLION DEBT FACILITY.TAKEDA PHARMACEUTICAL CO LTD - DEAL INCLUDES UPFRONT CASH AND EQUITY, AS WELL AS FUTURE CASH MILESTONES AND ROYALTIES ON NET SALES.  Full Article

Takeda Pharmaceutical Co - Notice Concerning Issuance Of New Stocks Through Third-Party Allotment
Tuesday, 14 May 2019 

May 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE CONCERNING ISSUANCE OF NEW STOCKS THROUGH THIRD-PARTY ALLOTMENT.TO ISSUE NEW STOCKS WORTH TOTAL 49,009,300,000 YEN TO THE MASTER TRUST BANK OF JAPAN.ISSUANCE PRICE IS 4,318 YEN PER SHARE.ISSUING 11,350,000 COMMON SHARES.ALLOTMENT IS ASSOCIATED WITH CONTINUATION OF STOCK GRANT SYSTEM (GLOBAL LONG-TERM INCENTIVE PLAN) FOR COMPANY GROUP MANAGEMENT IN JAPAN AND OVERSEAS IN FISCAL 2019.  Full Article

Takeda says To Sell Xiidra To Novartis For Up To $5.3 Bln
Wednesday, 8 May 2019 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES.TAKEDA PHARMACEUTICAL CO LTD - AGREES TO SELL XIIDRA TO NOVARTIS FOR UP TO $5.3 BILLION.TAKEDA PHARMACEUTICAL CO LTD - COMPANY TO ALSO DIVEST TACHOSIL TO ETHICON FOR APPROXIMATELY $400 MILLION.TAKEDA PHARMACEUTICAL CO LTD - DOES NOT EXPECT THESE DIVESTITURES TO HAVE A MATERIAL IMPACT ON ITS FY2019 CONSOLIDATED EARNINGS FORECAST.TAKEDA PHARMACEUTICAL CO LTD - INTENDS TO USE PROCEEDS FROM DIVESTITURES TO REDUCE ITS DEBT.TAKEDA PHARMACEUTICAL - FY2019 FORECAST WILL BE UPDATED AT LATER DATE TO REFLECT DIVESTITURES ONCE RELIABLE ESTIMATE OF IMPACT CAN BE MADE.TAKEDA PHARMACEUTICAL CO LTD - RECORDED FULL YEAR ADJUSTED NET SALES FOR TACHOSIL OF APPROXIMATELY $155 MILLION IN FISCAL YEAR ENDED MARCH 31, 2018..TAKEDA - ENTERED LONG-TERM MANUFACTURING SERVICES AGREEMENT, UNDER WHICH CO TO CONTINUE TO MANUFACTURE TACHOSIL PRODUCTS AND SUPPLY THEM TO ETHICON.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA WILL MAINTAIN OWNERSHIP OF MANUFACTURING FACILITY IN LINZ, AUSTRIA.  Full Article

Factbox: Purdue OxyContin settlement would rank among largest in pharma history

OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis, Reuters reported on Wednesday, citing people familiar with the matter.